16 completed, 10 recruiting, 4 terminated, 2 active not recruiting. 12 Phase 2, 7 Phase 1, 4 Not applicable, 4 Phase 3, 3 Early Phase 1.
Follow fluorodopa F 18: new trials by email Literature Review of fluorodopa F 18 trials Research Report on fluorodopa F 18
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors Computed Tomography, Fluorodopa F 18, Positron Emission Tomography - Malignant Brain Neoplasm | Phase 2 | Recruiting | Mayo Clinic | 47 | 2026-03-24 | 2026-04-28 |
| Ultralow Dose PET Imaging of 18F-FDOPA 18F-FDOPA - Heathy Volunteer, Parkinsonian Syndromes | Phase 2 | Enrolling by invitation | Akiva Mintz | 200 | 2025-05-12 | 2026-04-21 |
| Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics PET/CT with 18F-DOPA - Glioma | Phase 3 | Recruiting | Central Hospital, Nancy, France | 88 | 2023-06-13 | 2024-09-19 |
| Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18 - Glioblastoma | Phase 2 | Active not recruiting | Mayo Clinic | 170 | 2023-03-23 | 2026-07-30 |
| An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography - Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma | Completed | Mayo Clinic | 9 | 2022-11-10 | 2025-07-10 | |
| In Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy. Positron Emission Tomography (PET) with [18F]-FDOPA, Positron Emission Tomography (PET) with [18F]-FEOBV, Magnetic Resonnance Imaging (MRI) - Apathy | Phase 3 | Recruiting | University Hospital, Bordeaux | 30 | 2021-04-13 | 2026-06-10 |
| 18F-DOPA II - PET Imaging Optimization 18F-DOPA, Furosemide Injection - Congenital Hyperinsulinism, Neuroblastoma | Phase 3 | Recruiting | University of Alberta | 800 | 2021-01-20 | 2026-02-09 |
| Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism 18F-Fluoro Dopa PET/MRI Imaging - Hyperinsulinism | Phase 2 | Recruiting | Washington University School of Medicine | 100 | 2020-09-10 | 2025-12-19 |
| FDG and FDOPA PET Demonstration of Functional Brain Abnormalities Positron Emission Tomography, Computed Tomography, Multiparametric Magnetic Resonance Imaging Scan - Glioblastoma | Early Phase 1 | Unknown | University of Virginia | 5 | 2020-03-15 | 2020-03-24 |
| [18F]F-DOPA Imaging in Patients With Autonomic Failure [18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose - Autonomic Failure, Pure Autonomic Failure | Phase 1 | Recruiting | Daniel Claassen | 40 | 2020-02-04 | 2026-03-16 |
| 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging - Glioblastoma, Malignant Glioma | Phase 2 | Completed | Mayo Clinic | 43 | 2019-03-28 | 2025-07-03 |
| PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects 18F-FDOPA, 11C-DASB - Depression, HIV Infections | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 46 | 2018-11-20 | 2023-03-21 |
| 18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia Ralmitaront, Radiolabeled PET tracer [18F]-DOPA, Placebo - Schizophrenia | Phase 1 | Completed | Hoffmann-La Roche | 35 | 2018-11-07 | 2025-03-17 |
| Clinical Laboratory Evaluation of Chronic Autonomic Failure 13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine (11C-MRB) - Parkinson's Disease, Multiple System Atrophy | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 89 | 2018-09-06 | 2026-10-26 | |
| The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma Fluorine F 18 Fluorodopa, Intensity-Modulated Radiation Therapy, Positron Emission Tomography - Glioma | Phase 2 | Completed | Mayo Clinic | 21 | 2017-09-29 | 2023-03-14 |
| 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety 18F-DOPA - Congenital Hyperinsulinism, Neuroblastoma | Phase 3 | Completed | University of Alberta | 400 | 2017-06-29 | 2022-01-10 |
| Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin 18F-DOPA - Medullary Thyroid Cancer | Not applicable | Completed | Institut Claudius Regaud | 24 | 2017-03-22 | 2026-06-26 |
| Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients [18F]FDOPA PET/CT - Parkinson's Disease | Terminated | University of Saskatchewan | 18 | 2016-10-01 | 2023-06-02 | |
| Evaluation of Myocardial Sympathetic Denervation in Parkinson's Disease Using [18F]FDOPA [18F]-DOPA, PET-CT - Parkinson | Not applicable | Unknown | Tel-Aviv Sourasky Medical Center | 100 | 2015-08-01 | 2020-01-18 |
| FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas 6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine, PET/MRI, Surgical resection (standard of care) - Glioma, Malignant Glioma | Phase 1 | Terminated | Washington University School of Medicine | 11 | 2015-03-01 | 2016-11-30 |
Showing 20 of 38. Sign in to see all of them.
Glioma (11) · Congenital Hyperinsulinism (7) · Glioblastoma (6) · Hyperinsulinism (5) · Parkinson Disease (5) · Brain Neoplasms (4) · Hypoglycemia (4) · Insulinoma (4) · Neuroblastoma (3) · Neuroendocrine Tumors (3) · Astrocytoma (2) · Carcinoid Tumor (2) · Cushing Syndrome (2) · Endocrine System Diseases (2) · Ependymoma (2)
Mayo Clinic (9) · Children's Hospital of Philadelphia (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · University of Alberta (2) · Washington University School of Medicine (2) · Akiva Mintz (1) · Baylor College of Medicine (1) · British Columbia Cancer Agency (1) · Central Hospital, Nancy, France (1) · Cook Children's Health Care System (1) · Daniel Claassen (1) · Erik Mittra (1) · Hoffmann-La Roche (1) · Institut Claudius Regaud (1)
United States (30) · Canada (4) · France (3) · Israel (1)
Nadia N. Laack, M.D. (3) · Lisa J States, MD (2) · Lynnette K Nieman, M.D. (2) · Ana Maria Arbelaez, MD, MSCI (1) · Bijoy Kundu, PhD (1) · Catherine M Gordon, M.D. (1) · Daniel Lee, MD, PhD (1) · Deanna Hasenauer, Ph.D. (1) · Deanna Pafundi, PhD (1) · Debra Brinkmann, PhD (1)
PMID 39571596, PMID 17236890, PMID 17895314, PMID 19037637, PMID 23414871, PMID 24314195, PMID 24314196, PMID 29534198, PMID 31057686, PMID 31231443, PMID 33771703, PMID 34431366, PMID 37838323, PMID 42337037
P30CA124435 (1), P50CA108961 (1), R01CA178200 (1)